Andrew Reaume is the co-founder, President and CEO of Melior Discovery, an Exton, Pennsylvania preclinical contract research organization built around theraTRACE, a multiplexed in vivo phenotypic screening platform that runs a single drug candidate through a battery of animal disease models at once to uncover unexpected therapeutic uses. A geneticist by training with a Wharton MBA, he conceived the idea at Pfizer, left in 2005 to build it, and has since raised over $15 million in capital, closed more than $40 million in partnering deals, and pushed a repurposed compound, MLR-1023, into Phase 2 diabetes trials.
Brian Hotchkiss is the Chief Business Officer of Bexorg, a Yale University spinout building the first integrated AI and whole-human-brain platform for central nervous system drug discovery. A chemical engineer turned biotech dealmaker, he spent nearly seven years at Stealth BioTherapeutics shaping corporate strategy and helping land a transformative Alexion collaboration, then served as Chief Business Officer at Protego Biopharma before joining Bexorg. He pairs four graduate-level degrees in engineering, biology, and business with a career spent translating hard science into partnerships, capital, and commercial strategy.
J. Jean Cui is a medicinal chemist who has invented three FDA-approved cancer medicines and now runs the biotech she founded to do it again. As scientific founder, President and CEO of BlossomHill Therapeutics in San Diego, she designs small molecules built to outmaneuver the resistance mutations that defeat earlier drugs. Her crizotinib, lorlatinib and repotrectinib all began as chemistry problems she solved at the molecular level. In 2024 she was elected to the National Academy of Engineering. Her track record includes co-founding Turning Point Therapeutics, which Bristol Myers Squibb bought for $4.1 billion.
John D. Balian, MD is a physician-turned-executive who co-founded ClinChoice, one of the world's larger full-service contract research organizations, and serves as its CEO, International. He spent years inside the FDA, then ran drug safety and regulatory operations at Pfizer, Bristol-Myers Squibb and Johnson & Johnson before building a global CRO spanning the US, Europe and Southeast Asia. He is also a published novelist whose debut, Gray Wolves and White Doves, draws on his Armenian heritage and the Armenian Genocide.
Lisa M. Olson, Ph.D., is a biopharmaceutical research leader who became CEO of Milan-based clinical-stage biotech Enthera Pharmaceuticals in January 2024, after years on its board and as chair of its Scientific Advisory Board. Across two decades in immunology drug discovery - 15 years at AbbVie/Abbott where she helped advance 15 molecules into the clinic including Rinvoq, plus roles at Pfizer and as Chief Scientific Officer of Magenta Therapeutics - she has built a career turning biology into medicine. At Enthera she is steering the clinical development of Ent001, a first-in-class antibody targeting the IGFBP3/TMEM219 pathway for inflammatory bowel disease and type 1 diabetes.
Josh Carle is the Chief Business Officer of Hinge Bio, a Burlingame, California biotech building multivalent, multispecific antibody therapies on its GEM-DIMER platform. A dealmaker by trade, he has led or advised more than fifty strategic transactions worth over $2 billion in disclosed deal value, moving from Pfizer Oncology and Daiichi Sankyo to immuno-oncology startup Triumvira before joining Hinge Bio in January 2023 to steer its lead lupus program toward the clinic.
Peter Fedichev is a theoretical physicist turned longevity entrepreneur who co-founded Gero, a biotech AI company applying physics-based generative AI models to crack the root causes of aging. A former top-2 cited Russian physicist under 35, he traded quantum gases for aging clocks, building a platform that predicted biological age from wearable data before it was fashionable, secured a Pfizer collaboration, and landed a potential $250M deal with Chugai Pharmaceutical (Roche Group) in 2025 - all while publishing over 75 scientific papers and winning a $10,000 prize for winning a public debate on defeating aging.
Margo Georgiadis is CEO-Partner at Flagship Pioneering and co-founder & CEO of Montai Therapeutics, a biotech company using AI to discover drugs from natural compounds humans have consumed for centuries. A Harvard double-alumna (Phi Beta Kappa undergrad, Baker Scholar MBA), she has reinvented herself across industries - from McKinsey partner to Google Americas President, Mattel CEO, Ancestry.com CEO (overseeing its $5B sale to Blackstone), and now biotech pioneer building a platform that turns ancient botanicals and foods into precision medicines for chronic disease.
Terry Rosen is the CEO and co-founder of Arcus Biosciences, a clinical-stage biopharmaceutical company focused on developing combination cancer immunotherapies. A medicinal chemist by training with a Ph.D. from UC Berkeley, Rosen has spent over 30 years at the intersection of chemistry and oncology - from Abbott Laboratories and Pfizer to Amgen, and then co-founding Flexus Biosciences which sold to Bristol-Myers Squibb for $1.25 billion in 2015. He immediately used that platform to launch Arcus, which has since secured a landmark 10-year partnership with Gilead Sciences and advanced multiple molecules into pivotal clinical studies, including casdatifan, a best-in-class HIF-2α inhibitor showing strong results in kidney cancer.
Richard Yu is the Co-founder and CEO of Abalone Bio, an Emeryville, California-based biotechnology company pioneering AI-guided antibody drug discovery for notoriously hard-to-drug targets. With a PhD in Molecular Biophysics from Yale and a background spanning structural biology, systems biology, and biotech entrepreneurship, Richard built Abalone Bio's FAST platform - a high-throughput yeast cell screening system capable of evaluating 100 million antibody variants simultaneously. The company has secured partnerships with Pfizer and Mount Sinai, generated $7M in non-dilutive NIH grants, and published the world's first CB2 antibody agonist data, while positioning AI and large-scale functional datasets at the core of next-generation antibody therapeutics.